NovaBridge Biosciences Stock Price, News & Analysis

NovaBridge (Nasdaq: NBP) presented Phase 1 dose‑expansion data for ragistomig (4‑1BB × PD‑L1 bispecific) at ESMO‑IO on Dec 10, 2025. The 3 mg/kg every‑6‑weeks (Q6W) cohort (20 patients) showed comparable antitumor activity to 3 mg/kg every‑2‑weeks (Q2W) with a 58.8% disease control rate (DCR) vs 64.3% at Q2W and an objective response rate (ORR) of 11.8% vs 28.6% at Q2W (evaluable N=17 vs N=14).

Safety improved on Q6W: Grade ≥3 LFT elevation 5% vs 40%, TEAEs ≥Grade 3 were 50% vs 66.7%, no cytokine release syndrome reported, and no discontinuations due to TEAEs. Immunology data showed CD8+ effector/memory expansion with attenuated Treg increases. A 5 mg/kg Q6W cohort is enrolling.

NovaBridge (Nasdaq: NBP) announced that expanded Phase 1 dosing data for ragistomig (4-1BB x PD-L1 bispecific) will be presented in a poster at ESMO-IO on December 10, 2025. The company said the Q6W extended dosing interval met the study objective by delivering strong anti-tumor efficacy in PD-L1 non-responders while improving tolerability, including hepatic safety. Interim immunologic readouts showing CD8+ cell proliferation and memory T-cell activation will be included. The poster (Abstract #688) will be presented by Gerald Falchook, MD, at 5:30 PM GMT and supports planned progression to combination studies with partner ABL Bio.

NovaBridge (Nasdaq: NBP) subsidiary Visara appointed Cadmus C. Rich, MD, MBA as Chief Medical Officer and Carlos Quezada-Ruiz, MD, FASRS as Chair of its Scientific Advisory Board on Nov 20, 2025.

Visara said these hires strengthen clinical development for VIS-101, a bifunctional biologic targeting VEGF-A and ANG-2, and stated VIS-101 is expected to be Phase-3-ready in 2026. Management framed the appointments as validation of VIS-101’s opportunity and as contributors to completing Phase 2 and advancing registrational development.

NovaBridge (Nasdaq: NBP) said subsidiary Visara assigned its exclusive license for VIS-101 to Everest Medicines (HKEX: 1952) for development, manufacture and commercialization in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Everest will assume payment obligations under the assigned AskGene license and reimburse Visara for any upfront payment. VIS-101 is a bifunctional biologic targeting VEGF-A/ANG-2, completing a Phase 2 study in China and expected to be Phase-3-ready in 2026. NovaBridge also appointed Ian Woo, president and CFO of Everest Medicines, to its board.

The deal aims to leverage Everest’s regional clinical and commercialization expertise to accelerate VIS-101 development and patient access across Asia.

NovaBridge Biosciences (Nasdaq: NBP) announced it changed its corporate name from I‑Mab and will begin trading under the new ticker NBP at the open on October 30, 2025. Shareholder approval was granted on October 24, 2025 and no action is required by existing ADS holders. The company outlined a strategic shift to a global “hub‑and‑spoke” biotech platform, including a planned Hong Kong IPO and dual listings on Nasdaq and HKEX to broaden capital access.

Key program moves: the formation of subsidiary Visara and its acquisition of VIS‑101 (VEGF‑A/ANG2 bifunctional biologic); a ~$37M initial capital infusion into Visara; givastomig progressing toward a global randomized Phase 2 with first patient targeted in Q1 2026.